Background: ST-elevation myocardial infarction (STEMI) poses significant morbidity, mortality and economic burden in people with diabetes. We sought to determine the impact of diabetes on the short-term outcome and hospital costs post-percutaneous coronary intervention (PCI) for STEMI.

Methods: STEMI hospitalizations were selected in the Nationwide Readmissions Database from 2010 to 2014. From the patients who underwent PCI, we examined the 30‐day readmission, in-hospital mortality, and total cost according to the presence of diabetes, prior stroke, and prior MI. All statistical analyses were performed using R statistical software version 4.1.2.

Results: Among 539,171 index STEMI hospitalizations for primary PCI, 10.1% were readmitted within 30 days and 4.6% died in hospital. The readmission rates were 10.2%, 12.9%, 14.4%, 17.5%, and 18.4% in the reference (i.e., no diabetes, prior MI or stroke) , diabetes-only, diabetes and MI, diabetes and stroke, diabetes, MI, and stroke groups, respectively (P<0.001) . The corresponding adjusted hazard ratios for 30-day readmission were 1.14 (95% CI 1.10-1.18) , 1.23 (1.12-1.35) , 1.24 (1.10-1.39) , and 1.29 (0.99-1.68) . In-hospital mortality rates during index hospitalization were 4.3%, 5.3%, 5.5%, 7.2%, and 7.4% in the reference, diabetes-only, diabetes and MI, diabetes and stroke, diabetes, MI, and stroke groups, respectively (P<0.001) . The corresponding adjusted odds ratios for mortality were 1.24 (95% CI 1.15-1.33) , 1.55 (1.28-1.87) , 1.51 (1.22-1.87) , and 2.03 (1.27-3.25) . The median overall cost increased by 4.5% and 11.8% in the diabetes-only group and diabetes, MI, and stroke group, respectively, compared with the reference group (P<0.001) .

Conclusion: Within 30 days of PCI for STEMI, diabetes increases readmission rate, in-hospital mortality, and financial burden with and without prior CVD. These findings underscore the importance of aggressive optimization in STEMI patients with diabetes.

Disclosure

Y. Kang: None. S. Jang: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.